Metrics to compare | LASA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLASAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.6x | 10.6x | −0.3x | |
PEG Ratio | −0.03 | 0.14 | 0.00 | |
Price/Book | 0.5x | 0.8x | 2.6x | |
Price / LTM Sales | 4.0x | 0.6x | 2.9x | |
Upside (Analyst Target) | - | 0.0% | 64.3% | |
Fair Value Upside | Unlock | 18.6% | 10.0% | Unlock |
Lasa Supergenerics Limited engages in the manufacturing API bulk drugs products in India and internationally. It offers API products, such as fenbendazole, toldimphos sodium, cyromazine, albendazole, riclabendazole, rafoxanide, ornidazole, 2,6-diiodo-4-nitrophenol, ricobendazole, oxfendazole, closantel base, closantel sodium, nitroxynil, halquinol, and oxyclozanide; and Other API products. The company also provides animal feed ingredients; and reagents for therapeutic use. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.